Business
Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences
-- Clinical Data, Epidemiology and Health Economics and Outcomes Research to be Shared at Psych Congress, ISAD Conference and NEI Congress -- DUBLIN, Oct. 29,
About this update from Alkermes Plc
[{"type":"text","content":"-- Clinical Data, Epidemiology and Health Economics and Outcomes Research to be Shared at Psych Congress, ISAD Conference and NEI Congress --\n\n\nDUBLIN, Oct. 29, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present research from its psychiatry and addiction portfolios at upcoming scientific conferences this fall. The meetings include:\nPsych Congress (Oct. 29-Nov. 1, San Antonio and virtual); International Society for Affective Disorders (ISAD) Conference (Nov. 3-4, virtual); Neuroscience Education Institute (NEI) Congress (Nov. 4-7, Colorado Springs, Colo. and virtual). \"Alkermes has been at the forefront of developing medicines in the fields of psychiatry and addiction for many years, and we remain committed to helping people living with these serious, chronic diseases,\" said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes. \"We are proud to participate in important scientific exchange with key thought leaders and clinicians at these medical congresses and hope these data meaningfully contribute to the clinical community's knowledge base and approach to care for these patient populations.\"\nHighlights of the upcoming presentations include: \nResults from a cross-sectional online survey of clinical sites examining the impact of the COVID-19 pandemic on clinic operations, the use of telepsychiatry, and on care management for patients with schizophrenia treated with long-acting injectable antipsychotic medications; New findings from a health insurance claims analysis assessing opioid prescription dispensing patterns among individuals with schizophrenia or bipolar disorder compared to matched controls over time; Findings from a structured benefit-risk assessment evaluating a combination of olanzapine and samidorphan for the treatment of adults with schizophrenia and bipolar I disorder.The full list of Alkermes' presentations by meeting includes: \nPsych Congress, Oct. 29-Nov. 1, 2021 In-Person and Virtual Posters\nPoster #109: Opioid Prescription Dispensing Patterns in Patients With Schizophrenia: Real-World Evidence From the IBM® MarketScan® Research Databases Poster #110: Opioid Prescription Dispensing Patterns in Patients With Bipolar Disorder: Real-World Evidence From the IBM® MarketScan® Research Databases Poster #108: A Structur...